Trials / Completed
CompletedNCT06333548
Cord Blood Alarin Levels in Term Babies
Comparison of Cord Blood Alarin Levels in Term Babies According to Birth Weight
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 87 (actual)
- Sponsor
- Konya City Hospital · Academic / Other
- Sex
- All
- Age
- 1 Minute – 5 Minutes
- Healthy volunteers
- Not accepted
Summary
In this study, alarin levels in the cord blood of babies with large birth weights will be compared with babies of normal weight. Thus, the investigators aimed to find out whether there is a relationship between babies' birth weights and alarin.
Detailed description
Studies have shown that the galanin neuropeptide family plays a role in regulating appetite, insulin resistance, obesity, hypertension and metabolism. Alarin is a peptide consisting of 25 amino acids. Current research shows that allerin plays an important role in the emergence and development of diabetes and obesity. There are studies that found that the serum alarin level increased significantly in patients with impaired glucose tolerance and type 2 diabetes mellitus. Additionally, studies have found that both non-obese and obese type 2 diabetes mellitus serum alarin levels increase. Studies in the literature are related to adults, and there are no studies on alarin levels in newborn babies. Based on the alarin studies available in the literature, the investigators determined whether there is a relationship between the alarin level and the baby's birth weight by comparing the alarin level in the cord blood of babies with a high birth weight according to their gestational age (both babies of diabetic mothers and babies of non-diabetic mothers) compared to babies whose birth weight is within the normal range. the investigators aimed to find it.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Appropriate for gestational age , small for gestational age, large for gestational age, Baby of mother diagnosed with GDM | No intervention |
Timeline
- Start date
- 2023-09-18
- Primary completion
- 2023-12-23
- Completion
- 2024-01-15
- First posted
- 2024-03-27
- Last updated
- 2024-03-29
Locations
1 site across 1 country: Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT06333548. Inclusion in this directory is not an endorsement.